Actively Recruiting
Study of Immune Gene Variations and Antibody Patterns to Detect Early Liver Cancer in People with Hepatitis C
Led by Centro di Riferimento Oncologico - Aviano · Updated on 2024-12-05
1000
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Hepatitis C virus HCV infects over 185 million people worldwide and is a major risk factor for developing liver cancer called hepatocellular carcinoma HCC. Although direct-acting antiviral DAA treatments have improved virus eradication, the risk of HCC remains, so careful monitoring is still needed. This research aims to evaluate new blood biomarkers, including antibodies to specific HCV proteins and genetic markers related to immune response, to help develop an early screening method for liver cancer in people with chronic HCV infection. The study will examine the presence of antibodies against HCV peptides, the expression of interferon lambda 4 IFNL4, and interactions involving specific human leukocyte antigen HLA receptors. It will also study the immune environment linked to IFNL4 and HLA-E expression in patients undergoing surgery for HCC or those with advanced liver cancer. These evaluations will help understand the role of these immune markers in the progression of HCC in HCV-positive individuals. Participants will be followed for up to 2 years during which researchers will measure differences in antibody profiles between patients with and without chronic HCV infection and among those receiving or not receiving DAA therapy. The study will also assess relationships between antibody levels, viral load, HCV genotype, and immune gene variants. Data collected will include blood samples and questionnaire responses to monitor immune markers and disease progression over time.
CONDITIONS
Brief Title
Characterization of Immune Genotypes and Antibody Profiles to Foster the discoVERY of diagnosticbioMARKERS of Liver Cancer Development
Research Team
V
Valli De Re, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here